- Home
- GLUE vs OTLY Comparison
GLUE vs OTLY Comparison
Compare GLUE & OTLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- OTLY
- Stock Information
- Founded
- GLUE 2019
- OTLY 1994
- Country
- GLUE United States
- OTLY Sweden
- Employees
- GLUE N/A
- OTLY N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- OTLY Packaged Foods
- Sector
- GLUE Health Care
- OTLY Consumer Staples
- Exchange
- GLUE Nasdaq
- OTLY Nasdaq
- Market Cap
- GLUE 351.2M
- OTLY 303.5M
- IPO Year
- GLUE 2021
- OTLY 2021
- Fundamental
- Price
- GLUE $4.79
- OTLY $15.07
- Analyst Decision
- GLUE Buy
- OTLY Buy
- Analyst Count
- GLUE 2
- OTLY 5
- Target Price
- GLUE $13.50
- OTLY $19.60
- AVG Volume (30 Days)
- GLUE 468.8K
- OTLY 159.5K
- Earning Date
- GLUE 08-11-2025
- OTLY 07-23-2025
- Dividend Yield
- GLUE N/A
- OTLY N/A
- EPS Growth
- GLUE N/A
- OTLY N/A
- EPS
- GLUE 0.08
- OTLY N/A
- Revenue
- GLUE $159,487,000.00
- OTLY $828,200,000.00
- Revenue This Year
- GLUE $49.02
- OTLY $4.68
- Revenue Next Year
- GLUE N/A
- OTLY $4.78
- P/E Ratio
- GLUE $61.82
- OTLY N/A
- Revenue Growth
- GLUE 14889.38
- OTLY 4.43
- 52 Week Low
- GLUE $3.50
- OTLY $6.00
- 52 Week High
- GLUE $12.40
- OTLY $20.80
- Technical
- Relative Strength Index (RSI)
- GLUE 40.93
- OTLY 65.35
- Support Level
- GLUE $5.22
- OTLY $14.30
- Resistance Level
- GLUE $5.64
- OTLY $15.50
- Average True Range (ATR)
- GLUE 0.38
- OTLY 0.77
- MACD
- GLUE -0.11
- OTLY -0.02
- Stochastic Oscillator
- GLUE 0.68
- OTLY 83.15
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.